Prostatic glandular epithelial cells express protein kinase Ce (PKCe), an oncoprotein that coordinately disrupts the reactivation of the tumor suppressor Rb, derepressess transcriptional elongation of the c-myc oncogene, and propagates survival signals in LNCaP cells. Since the activation of such a program may contribute to the progression of human prostate cancer, a proteomic analysis was performed to gain a more global perspective on the signaling network that PKCe might be capable of engaging in prostate cancer cells. Using CWR22 xenografts, we identified at least 18 different structural, signaling, and stress-related proteins that associated with PKCe, including an interaction with the proapoptotic protein Bax that was novel to recurrent CWR22 tumors. An investigation into the biological significance of the PKCe association with Bax provided the first evidence of an inverse relationship between endogenous levels of PKCe and susceptibility of prostate cancer cells to the apoptotic effects of phorbol esters. Western blot and antisense experiments demonstrated that CWR-R1 cells expressed moderate levels of PKCe and relied on this protein to survive in the presence of phorbol esters, while the apoptosis normally induced by phorbol esters in PKCe-deficient LNCaP cells was dependent on the presence of Bax. Forced expression of PKCe in LNCaP cells was sufficient to confer a significant resistance to phorbol esters and this resistance was associated with an inhibition ofIntroduction Prostatic epithelial cells that survive androgen deprivation therapy engage multiple molecular pathways to escape their normal apoptotic fate, to restore the expression of androgen-responsive genes, and to disrupt the growth-restraining activity of the retinoblastoma (Rb) family of transcriptional represser proteins (Gregory et al., 1998; Fribourg et al., 2000; Mousses et al., 2001 ). The present study has focused on the first of these hallmarks of advanced carcinoma of the prostate (CaP), because defects in the apoptotic machinery are likely to be an important contributing factor in the resistance of some CaP cells to chemotherapy or irradiation and to the recurrence of CaP after androgen deprivation. One well-characterized example of the progression to an apoptosis-resistant stage is provided by the differential responses of androgensensitive and -insensitive (AI) CaP cell lines to agents such as phorbol 12-myristate 13-acetate (PMA) (Day et al., 1994; Young et al., 1994; Powell et al., 1996; Zhao et al., 1997; Henttu and Vihko, 1998; Fujii et al., 2000; Gschwend et al., 2000) . As documented in these and other studies, PMA is a protein kinase C (PKC) agonist that selectively activates a mitochondrial-dependent pathway in the androgen-sensitive lymph node CaP (LNCaP) but not AI (DU145 and PC3) CaP cell lines. Additional examples of agents that preferentially induce cell death in the LNCaP model of early CaP include tumor necrosis factor-alpha (TNFalpha), bryostatin 1, thapsigargin, N-(4-hydroxyphenyl)retinamide, and inhibitors of phosphatidylinositol-3 0 -kinase (PI3-K) (Chen et al., 1999; Gschwend et al., 2000; Murillo et al., 2001; Dhanalakshmi et al., 2002; Engedal et al., 2002) . Thus, recurrent CaP cells tend to be extremely resistant to the apoptogenic signals triggered by diverse agents.
Understanding the survival strategies employed by certain recurrent CaP cells could be instructive in targeting the proteins that permit these cells to overcome the stress of androgen deprivation and chemotherapy. Since intracellular signaling pathways responsible for triggering the programmed death of chemosensitive CaP cells must be understood fully, the apoptotic response of LNCaP cells to PMA has interested CaP researchers for many years. Increasing evidence suggests that both PKCa and PKCd may directly participate in the PMAinduced apoptosis of LNCaP cells (Powell et al., 1996; Fujii et al., 2000; Gschwend et al., 2000; Garcia-Bermejo et al., 2002) . For example, overexpression of wild-type PKCa or PKCd potentiates the apoptotic effects of PMA in LNCaP cells (Fujii et al., 2000; Gschwend et al., 2000; Qiao et al., 2001; Zhao and Day, 2001) , while the introduction of a dominant-negative PKCd mutant can effectively inhibit this response (Fujii et al., 2000) . Bcl-2 overexpression also partially inhibits PMA-induced apoptosis of LNCaP cells (Fujii et al., 2000) , suggesting the possible involvement of proapoptotic Bcl-2 family members. It has been proposed that ceramide biosynthesis may be a prerequisite for the cell death induced by PKCd (Garzotto et al., 1998; Sumitomo et al., 2002) . However, PMA-induced production of ceramide appears to preferentially induce necrosis, rather than apoptosis, in LNCaP cells (Engedal and Saatcioglu, 2001) . Alternative explanations for the PKC-mediated apoptosis of LNCaP cells have emphasized the possible involvement of the c-myc oncogene (Zhao and Day, 2001 ) and c-Jun N-terminal kinase (JNK; Engedal et al., 2002) . Studies have shown that when LNCaP cells are treated with PMA, there is a rapid and sequential activation of Rb and transcriptional repression of c-myc that precedes the onset of apoptosis (Zhao and Day, 2001 ). More recently, it was reported that JNK activity is activated by PMA and that LNCaP cells overexpressing the JNK inhibitory protein (JIP) are resistant to PMA-induced apoptosis (Engedal et al., 2002) . These data suggest that Rb and JNK may play important roles downstream of PKCa/PKCd in one or more of the mitochondrial-dependent apoptotic pathways that LNCaP cells possess.
There is now evidence that PKCe may counterbalance the influence of PKCa and PKCd on the growth and survival of human CaP cells Wu et al., 2002) . We have shown previously that the basal level of PKCe protein is consistently elevated in recurrent CWR22 xenograft tumors and subconfluent cultures of AI-CaP cells (DU145 and PC3), relative to their androgen-sensitive counterparts (CWR22 tumors and LNCaP cells; Wu and Terrian, 2002; Wu et al., 2002) . Using antisense PKCe oligodeoxynucleotides (ODN), it was demonstrated that a reduction in the basal levels of endogenous PKCe could significantly inhibit the AI proliferation of DU145 and PC3 cells . In LNCaP cells, we found that PKCe overexpression was sufficient to transform these cells into variants that were no longer sensitive to the apoptotic effects of PMA in vitro and capable of rapidly initiating tumor growth in both normal and surgically castrated male nude mice . These and other findings established that PKCe could play a dominant role in determining the fate of CaP cells following androgen deprivation and are in agreement with recent reports that this oncoprotein is capable of using multiple molecular mechanisms to evade apoptosis, and increase proliferation, in a variety of human cancer cell lines (Basu et al., 2002; Ding et al., 2002) .
In this study, we employed 2D gel electrophoresis (2DE) to obtain an unbiased comparison of PKCe signaling complexes in specimens from CWR22 and recurrent CWR22 xenografts. The aim was to identify molecules that could potentially participate in PKCe signaling throughout the recurrence of CaP and to gain a more global perspective on how PKCe signaling may transduce survival signals within certain CaP cells. This proteomic approach has proven to be an effective method for examining the molecular composition of PKCe modules that are assembled in cardiomyocytes, where PKCe signaling is required to survive an ischemic insult (Ping et al., 2001; Edmondson et al., 2002; Song et al., 2002) . Our analysis revealed that PKCe is physically associated with many of the same molecules in CWR22 xenografts and in cardiomyocytes, including certain structural, signaling, and stress-activated proteins. In addition, we report a previously uncharacterized interaction between PKCe and the proapoptotic protein Bax that was novel to recurrent CWR22 xenografts. Antisense, cellular fractionation, and confocal microscopy provided several independent lines of evidence to support the hypothesis that interactions between PKCe and Bax may limit the proapoptotic activity of PMA in cultured CWR-R1 cells, and LNCaP cells overexpressing PKCe, by interfering with the activation and mitochondrial integration of Bax. Finally, immunohistochemical studies showed that while some epithelial cells express PKCe in benign prostate tissue and clinically localized tumors examined prior to androgen deprivation therapy, the majority of recurrent prostate cancer epithelial cells are PKCe-positive. These studies introduce a novel protein interaction that could possibly enable certain CaP cells to survive the involution-regeneration cycle that is often induced after androgen-deprivation therapy.
Results

Identification of a novel interaction between PKCe and Bax
In an effort to identify some of the proteins that could conceivably link PKCe signaling to the survival and recurrent growth of CaP tumors in vivo, we performed a comparative analysis of PKCe immunoprecipitates isolated from CWR22 and recurrent CWR22 tumor lysates, using 2DE for visualization of protein profiles. This analysis indicated that PKCe was associated with at least 18 different proteins in CWR22 tumor lysates (Figure 1a) , while fewer proteins coimmunoprecipitated with PKCe in recurrent CWR22 tumor lysates (Figure 1b) . Superimposition of these proteomic profiles, from three independent experiments, indicated that several interactions with PKCe were unique to either the CWR22 or recurrent CWR22 xenografts. Proteins found to be associated with PKCe both in CWR22 and recurrent CWR22 xenografts included b-actin (Figures 1a and b, spot 1) , PKB/Akt, androgen receptor, Bag-1L, caveolin-1, Lck, and Raf-1 and data not shown). The implications of these, and other, protein interactions are the subject of an ongoing investigation. Here we have focused on an association of PKCe with a protein having coordinates (pIB5.1 and M r B23 kDa) that approximated those of the proapoptotic protein Bax (Figure 1b , spot 2). Recent evidence indicates that the capacity to inhibit Bax mitochondrial integration and apoptotic activity may not be restricted to the Bcl-2 subfamily of antiapoptotic proteins (Samuel et al., 2001; Nomura et al., 2003) . Given the observations that PKCe selectively interacted with Bax in recurrent CWR22 xenografts (Figure 1 ) and suppresses the apoptotic effects of PMA in LNCaP cells , we hypothesized that an association of PKCe with Bax might promote CaP cell survival and block PMA-induced apoptosis.
Using CWR-R1 cells as an in vitro model of tumor regeneration in the absence of testicular androgen (Gregory et al., 2001a) , we performed reciprocal coimmunoprecipitation assays that confirmed that PKCe binds to Bax, and Bax binds to PKCe, in the absence of a protein cross-linker and in the presence of either 1% Triton X-100 or 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (Chaps) (Figures 1c and d) . Neither of these proteins was detected in controls that had been treated with IgG alone (Figures  1c and d) . In the presence of Triton X-100, it is possible that the association of PKCe with Bax resulted from a direct effect of this nonionic detergent that causes the Bax protein to nonselectively oligomerize with other proteins (Hsu and Youle, 1998; Suzuki et al., 2002) . However, that is unlikely to explain the interaction observed in the presence of Chaps, as this zwitterionic detergent has been shown to keep Bax in its native conformation. These observations indicated that the association between PKCe and Bax was relatively stable and had been established prior to cell lysis.
PKCe protects CWR-R1 cells from the apoptotic effects of PMA
In two previous studies, we have been unable to detect PKCe in LNCaP lysates using Western blotting techniques Wu et al., 2002) and it is well established that these cells do not survive in the presence of PMA (Figure 2a ; Henttu and Vihko, 1998) . In contrast, subconfluent cultures of CWR-R1 cells express moderate levels of PKCe protein and are relatively insensitive to even high concentrations of PMA (100 nm; Figure 2a ). These characteristics made it possible to conduct an antisense experiment to determine whether a depletion of endogenous PKCe protein could influence the susceptibility of a CaP cell line to PMA. The antisense PKCe ODN used in these experiments has previously been shown to selectively and effectively downregulate translation of PKCe mRNA in the CWR-R1 cell line . When subconfluent cultures of CWR-R1 cells were pretreated using an identical protocol for suppression of PKCe translation and then exposed to PMA for 20 h, there was a fivefold increase in the percentage of apoptotic cells identified using the acridine orange-ethidium bromide staining method ( Figure 2b ). These data indicated that CWR-R1 cells rely on endogenous PKCe to survive the apoptotic signals triggered by PMA.
Bax mediates the commitment of LNCaP cells to PMA-induced apoptosis
Since parental CWR-R1 cells did not respond to PMA treatments (Figure 2) , we adopted the use of the LNCaP cell line as a model for investigating mechanisms of PMA-triggered apoptosis that might be influenced by interactions of PKCe with Bax. There is convincing evidence that the overexpression of Bcl-2 is capable of protecting LNCaP cells against PMA (Fujii et al., 2000) . However, the question of whether Bax directly participates in the commitment of LNCaP cells to the apoptosis induced by PMA has not been investigated. To determine whether a reduction in basal levels of Bax protein would protect LNCaP cells that had been exposed to PMA, we used a combination of two antisense Bax ODN that have been shown to suppress Bax expression in several cell types (Dibbert et al., 1999) . An immunoprecipitation and immunoblot analysis indicated that these antisense Bax ODN had reduced the basal levels of Bax protein by about 50% in subconfluent cultures of LNCaP cells (Figure 3a) . Under identical conditions, neither Lipofectin alone nor Lipofectin plus the scrambled Bax ODN altered the steady-state concentration of Bax protein. Following these treatments, LNCaP cells were exposed to either dimethylsulfoxide alone or 100 nm PMA for 24 h and the induction of apoptosis was then quantified with acridine Subconfluent cultures of LNCaP and LNCaP/e cells were incubated in the absence or presence of 100 nm PMA for the time specified and equal amounts of precleared lysate were analysed for changes in Bax conformation by immunoprecipitating with the uBax 6A7 monoclonal antiserum before immunoblotting for total Bax protein (top two panels) or using the reverse protocol (bottom two panels). (c) Subconfluent cultures of LNCaP/e cells were incubated in the absence or presence of 100 nm PMA for 24 h before immunoprecipitating with secondary IgG alone (IgG) or with anti-PKCe antibodies before immunoblotting with anti-Bax antibodies and anti-caveolin-1 antibodies orange and ethidium bromide staining of apoptotic cells. These assays showed that 45-55% of the LNCaP cells that had been pretreated with Lipofectin alone or the scrambled Bax ODN had the morphologic appearance of apoptotic cells, while the apoptotic activity of PMA was completely blocked in cultures pretreated with antisense Bax ODN (Figure 3a) . These antisense studies supported the idea that PMA triggers apoptosis through a Bax-dependent mechanism in LNCaP cells (Fujii et al., 2000) .
PKCe is capable of restraining Bax activation and redistribution in LNCaP cells
The balance between apoptosis and survival often depends on the manner in which apoptotic and antiapoptotic members of the Bcl-2 protein family interact with one another (Antonsson, 2001) , although some reports disagree with this view (Knudson and Korsmeyer, 1997; Metcalfe et al., 1999) . Taken together, the available evidence suggests that Bax conformation is an important determinant of its subcellular localization (Suzuki et al., 2002) . Since Bax appeared to mediate the apoptotic effects of PMA in LNCaP cells (Figure 3a) and PKCe overexpression effectively blocks this response , it was important to determine whether PKCe overexpression inhibits this process by blocking Bax activation and mitochondrial integration.
Changes in Bax activity were examined using an antiBax 6A7 monoclonal antibody that specifically recognizes an active conformation of the Bax protein (Hsu and Youle, 1998) . Figure 3b indicates that active Bax can be detected using the anti-Bax 6A7 antibody in untreated and actively proliferating cultures of LNCaP cells. However, increased amounts of activated Bax were immunoprecipitated from Chaps cell lysates after LNCaP cells had been exposed to 100 nm PMA for 8-16 h. In contrast, LNCaP cells protected by PKCe overexpression (LNCaP/e) demonstrated a block in this response in that no or very little active Bax was detected in these 6A7 immunoprecipitates (Figure 3b , upper two panels). The same result was obtained using the reverse protocol to immunoblot total Bax immunoprecipitates with the 6A7 monoclonal antibody (Figure 3b , lower two panels). An immunoblot analysis of PKCe immunoprecipitates demonstrated that, under these conditions, caveolin-1 and cytosolic Bax remained associated with PKCe in LNCaP/e cells during a prolonged exposure to PMA (Figure 3c ). Although the steady-state concentration of PKCe in LNCaP cell lysates was below the threshold for detection using Western blotting techniques, the protein could be detected by immunoprecipitation and immunoblotting with anti-PKCe antibodies. When probed using the anti-Bax N-20 antibodies, these LNCaP PKCe immunoprecipitates contained no detectable Bax protein (data not shown). Western blot analysis also demonstrated that the forced expression of PKCe in LNCaP cells did not alter the endogenous levels of the Bcl-2 family members Bcl-2, Bad, Bak, or Bid (data not shown). These findings suggested that when cytosolic concentrations of PKCe protein are sufficiently high, as in CWR-R1 and LNCaP/e cells, PKCe may become associated with Bax and inhibit Bax conformational changes normally induced by PMA.
Next, the ability of PKCe to influence the mitochondrial targeting of Bax in LNCaP cells was investigated. LNCaP and LNCaP/e cells were incubated in the absence or presence of PMA for 12 h prior to staining mitochondrial membranes, using Mitotracker Green FM, and endogenous Bax, using anti-Bax primary antibodies (N-20) followed by TXRD-conjugated secondary antibodies. Before exposing LNCaP and LNCaP/e cells to PMA, the pattern of Mitotracker staining was in the filamentous shape normally observed for mitochondria in living cells (Figure 4 ; Gao et al., 2001) . Under these resting conditions, foci of superimposed mitochondrial and Bax staining could occasionally be observed in individual LNCaP and LNCaP/e cells (Figure 4 , Merged). When exposed to PMA for 12 h, the number of viable LNCaP cells significantly decreased (Figure 2a (Figure 4 ). These and the data discussed above have provided the first evidence to support the hypothesis that Bax is required for PMAinduced apoptosis in CaP cells and that a novel direct, or indirect, interaction between PKCe and Bax might directly influence the commitment of CaP cells to apoptosis.
PKCe operates at a site upstream of cytochrome c release
The effects of PMA treatment on cytochrome c distribution within LNCaP and LNCaP/e cells were compared to determine whether enforced expression of PKCe interfered with the ability of PMA to disrupt mitochondrial integrity. Within a 12 h exposure to PMA, the subcellular distribution of cytochrome c immunostaining in LNCaP cells shifted from a normal filamentous shape characteristic of mitochondrial staining (Gao et al., 2001 ) to a punctuate and weaker intensity of staining (Figure 5a ). This dispersion of cytochrome c immunoreactivity was not observed in LNCaP/e cells treated with PMA (Figure 5a ). To further examine the distribution of cytochrome c, a subcellular fractionation and immunoblot analysis was performed using LNCaP and LNCaP/e cells. When LNCaP cells were cultured in the presence of PMA, cytochrome c was redistributed from mitochondria-enriched heavy membrane (M) fractions to the cytosolic (S) fractions prepared from LNCaP cells undergoing apoptosis (Figure 5b ). In contrast, cytochrome c was not detected in cytosolic fractions of LNCaP/e cells treated with an equimolar concentration of PMA and the proportion of cytochrome c detected in the mitochondria-enriched heavy membrane fraction was not reduced (Figure 5b ). The presence of the mitochondrial marker protein porin and absence of cytosolic actin (Figure 5b ) indicated mitochondrial enrichment of fraction M, while the absence of porin in fraction S (Figure 5b ) suggested a lack of mitochondrial contamination. Thus, when followed by indirect immunofluorescence on the single cell level or by cell fractionation, it was evident that the forced expression of PKCe prevented the mitochondrial release of cytochrome c.
Survival of PKCe-positive epithelial cells during the progression of CaP
Immunohistochemical comparisons of benign prostatic tissue and prostatic intraepithelial neoplasia indicate that the overall level of PKCe protein increases early in the genesis and progression of CaP in man (Cornford et al., 1999) . In the rat ventral prostate, however, PKCe expression decreases during the glandular involution . In contrast, focal sites of yellow staining were also evident in PMA-treated LNCaP/e cells, but there was a consistent decrease in the extent to which these staining patterns overlapped. Results are representative of six independent experiments. Scale bar is 10 mm that is induced by either surgical castration or androgendeprivation therapy (Montalvo et al., 2002) . These observations, together with the data presented here, indicated that the ability of PKCe to block certain forms of Bax-mediated apoptosis may not be sufficient to ensure the survival of CaP cells throughout the involution-regeneration cycle that is characteristic of recurrent CaP. However, an immunoblot analysis has recently shown that lysates of recurrent CWR22 tumors contain increased levels of PKCe protein, in comparison to the CWR22 tumors growing in an intact host . It was, therefore, important to resolve the issue of whether CaP cells expressing PKCe can survive to advance the recurrence of CaP. For this reason, an immunohistochemical study of PKCe expression was performed using primary tissue specimens of benign prostatic tissue (BPH) and human androgendependent and recurrent prostate cancers (Figure 6 ). Tissue morphology showed the characteristic glandular structure of BPH (Figure 6b ) and poorly differentiated recurrent CaP (Figure 6d ). Weak immunoperoxidase staining of PKCe was detected in the stroma of some prostate tissues, but this was not consistently observed. Rather, the pattern of immunostaining for PKCe was predominantly confined to the cytoplasm of basal and columnar epithelial cells of benign and malignant specimens ( Figure 6 ). Prior to androgen-deprivation therapy, a majority of these cells expressed PKCe in androgen-dependent CaP (Figure 6c) . In recurrent CaP, the relative number of PKCe-positive tumor epithelial cells remained equivalent to, or greater than, that observed in androgen-dependent CaP (Figure 6c and  d) . However, a quantitative analysis of the mean optical density for immunopositive regions within individual CaP cells did not differ within these tissues. For benign and malignant samples, the mean optical densities for PKCe immunostaining were 0.2970.02 and 0.2870.03, respectively. These data were consistent with a model of Mitochondria-enriched heavy membrane (M) fractions and cytosolic (S) fractions were isolated by differential centrifugation and equal amounts of protein were immunoblotted using anticytochrome c antibodies. Results are representative of three independent assays. In an additional assay, both fractions M and S were immunoblotted using antiporin and antiactin antibodies to confirm that fraction M was enriched in mitochondrial membranes and that fraction S was not contaminated by mitochondria 
Discussion
Among the PKC isozymes present in human prostatic epithelial cells, PKCe appears to counterbalance the influence of PKCa and PKCd by favoring a program that results in the malignant progression of CaP Wu et al., 2002) . In this paper, several substantive findings have been reported that should contribute to continuing advances in our understanding of the molecular mechanisms that PKCe may employ in CaP cells to overcome the diverse challenges to survival that are likely to be encountered during the involution and regrowth of CaP. First, a functional proteomic analysis and reciprocal pull-down assays have provided the first evidence of an association between PKCe and the proapoptotic protein Bax in recurrent CWR22 xenografts and cultured CWR-R1 cells. Second, the data indicate that CWR-R1 cells, which express moderate levels of PKCe and are naturally resistant to the proapoptotic effects of PMA, rely on PKCe for this protection. Third, it has been shown that PKCe-deficient LNCaP cells can be protected from PMA by specifically targeting, and suppressing translation of, Bax mRNA using a conventional antisense strategy. Fourth, there is now evidence that at least one of the Bax-dependent pathways committing LNCaP cells to an apoptotic fate can be neutralized by simply overexpressing PKCe. Finally, the survival and apparent expansion of PKCepositive cells that can be observed in biopsies of androgen-dependent vs recurrent CaP implies that the function of this oncoprotein could be an important and early determinant of cell fate.
A major goal of the experiments described here was to identify molecular components that are associated with PKCe in CaP tumor cells and to determine whether these proteins contribute to the oncogenic activity of this novel PKC isozyme. More experimental work will be required to complete this analysis and that work is ongoing. Here we have attempted to gain some insight into the biological significance of an intriguing interaction that was first detected in recurrent CWR22 xenografts and involved the proapoptotic protein Bax. Considered in their entirety, our results suggest that PKCe may advance the survival of CaP cells by inhibiting Bax conformational rearrangements that are important for Bax oligomerization, mitochondrial integration, and cytochrome c release. Many details regarding the mechanisms controlling Bax oligomerization and bioactivity have not been resolved. It is widely accepted that the C-terminal tail of Bax contains a conserved hydrophobic motif that appears to be critical for the mitochondrial targeting of Bax and its apoptotic activity (Antonsson, 2001) . While mutational studies have also implicated the Bax BH3 domain in Baxmediated oligomerization and apoptosis, the role of this domain is less certain. Antibodies raised against a Bax BH3 epitope indicate that a conformational rearrangement exposing this domain precedes the mitochondrial translocation of this protein in response to apoptotic stimuli (Gilmore et al., 2000) . However, a structural analysis of Bax shows that its C-terminal a9 helix, which contains the BH3 domain, establishes an extremely stable interface with the hydrophobic BH3-binding pocket of this protein (Suzuki et al., 2002) . Thus, the stability of this intramolecular interaction may prevent dimer formation at this site in the cytosol of healthy cells. Alternative mechanisms for the formation of Bax homo-and hetero-oligomers include helical packing/ bundling at the interface between Bax and its binding partners (Suzuki et al., 2002) . The N-terminus of PKCe contains a C2-like domain that may be important for its intracellular targeting and interactions with other proteins (Schechtman and Mochly-Rosen, 2001 ). However, crystal structures of the PKCe-C2 domain (residues Met 1 to Gly
138
) consist of an eight-stranded, antiparallel, b-sandwich (Ochoa et al., 2001 ) that would not be suited for helical packing/bundling with a protein such as Bax. PKCe does not contain a BH3-like domain and, until the complete crystal structure of PKCe has been resolved, it is not possible to predict whether the surface of this protein presents a suitable interface for interacting directly with Bax protein. Given the numerous proteins that are associated with PKCe modules within CWR22 tumors in vivo, the interaction of PKCe with Bax is likely to be indirect and may be mediated by one or more intermediary proteins. In any case, PKCe overexpression is capable of suppressing Bax activation and translocation from the cytosol to mitochondria in LNCaP cells exposed to cytotoxic concentrations of PMA. The studies described emphasize the importance of addressing the basic question of how PKCe influences the bioactivity of Bax and developing a detailed molecular description of this novel protein interaction.
At least three major signaling pathways control the activity of initiator caspases and apoptotic cell death: intrinsic mitochondrial-dependent and ER stress-induced pathways and an extrinsic death receptor pathway. While the data presented here may offer a plausible explanation of how PKCe might effectively neutralize one arm of this complex signaling network, additional levels of protection are certain to be required in order to escape the fate of most CaP cells when subjected to androgen-deprivation therapy. An immunohistochemical analysis of recurrent CaP specimens makes it clear that some CaP cells expressing PKCe have acquired the capacity to meet these challenges. In addition to disrupting the activation of Bax, there is good evidence that PKCe signaling may be capable of supporting the autocrine growth of LNCaP cells and stimulating the production and release of caveolin-1, an important survival factor in the growth of prostatic tumors Wu et al., 2002) . The ability of PKCe to disrupt one or more of the stress-induced or death receptor pathways has not been investigated in CaP cells. However, it has recently been reported that TNF-a triggers the cleavage of PKCe by caspase-7 and that the C-terminal fragment generated by this process functions as an antiapoptotic protein in MCF-7 breast cancer cells (Basu et al., 2002) . Moreover, the forced expression of PKCe in lung cancer cells confers a significant resistance to the chemotherapeutic drugs, doxorubicin and etoposide (Ding et al., 2002) .
In summary, we have identified an additional mechanism that PKCe may employ to propagate the growth and survival of certain CaP cells. PKCe is a required component of the CWR-R1 survival pathway that operates to protect these cells from PMAinduced apoptosis and drives the transcriptional elongation of the c-myc oncogene . In LNCaP cells, PKCe-mediated survival signals can supplant the requirement for serum-derived growth factors , and by altering the topological response of Bax within the mitochondrial death signaling pathway, PKCe may subvert the programmed death of selected CaP cells and promote CaP progression. It is clear from our recent investigations on PKCe signaling that multiple effector signaling pathways must participate in generating the phenotypic responses of CaP cells to PKCe-mediated activity; including the Raf/MEK/ERK kinase cascade, the Rb/ E2F pathway, the transcription factor c-Myc, and mitochondrial-dependent apoptosis pathways. Understanding how these effector pathways interconnect should provide many valuable insights for the development of meaningful treatments.
Materials and methods
Two-dimensional electrophoresis
PKCe immunoprecipitates, prepared from CWR22 and recurrent CWR22 tumor lysates, were separated by 2DE. The protein A-anti-PKCe complex was solubilized with 250 ml 2-D buffer (9.5 mm deionized urea, 4% Chaps, 18 mm 1,4-dithiothreitol, 0.01% bromophenol blue, 2% 3-10 immobilized pH gradient [IPG] buffer) and resolved on IPG strips (Amersham Pharmacia, Piscataway, NJ, USA) by isoelectric focusing (IPGPhor, Amersham Pharmacia). IPG strips were then re-equilibrated and the 2-D electrophoresis was performed for between 60 and 100 K total V/h. Gels were then stained, dried, digitized, and analysed using DECODON Delta2D (DECODON, Greifswald, Germany) software for the differential display of CWR22 and recurrent CWR22 2-D gels and a search engine designed to predict the identity of proteins isolated on 2-D gels (www.ca.expasy.org/tools/ tagident.html). Data presented are representative of three independent experiments.
Cell lines and culture conditions
LNCaP cells were obtained from the American Type Culture Collection (Manassas, VA, USA; ATCC CRL-1740) and maintained in culture as previously described . The CWR-R1 cell line was clonally selected for AI growth from recurrent CWR22 xenograft tumors as described (Gregory et al., 2001a) . LNCaP cell culture reagents were purchased from Invitrogen (Rockville, MD, USA). CWR-R1 cells were cultured in Richter's Improved MEM (Invitrogen) supplemented with 100 ng/ml epidermal growth factor and 10 mg/ml insulin/transferrin/ selenium (BD Biosciences; Bedford, MA, USA), 10 mm nicotinamide, 900 ng/ml linoleic acid, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2% fetal bovine serum (FBS; Invitrogen).
Expression plasmid and transfection into LNCaP cells
LNCaP cells with pLXSN recombinant retrovirus harboring the gene for p3/PKCe (LNCaP/e) were prepared as described (Prekeris et al., 1998; Wu et al., 2002) .
Coimmunoprecipitation
Whole-cell lysates were prepared from cultures of LNCaP, LNCaP/e, and CWR-R1 cells and from frozen CWR22 and recurrent CWR22 tumors, as described previously (Gregory et al., 2001b; Wu et al., 2002) . Tumor lysates were precleared with 20 ml of protein A agarose (Invitrogen) at 41C for 30 min before sedimenting the agarose beads at 13 000 g for 5 min. Precleared supernatants were incubated with polyclonal antiPKCe or anti-Bax antiserum on a rotator overnight at 41C. Immunocomplexes were precipitated by adding 50 ml Protein A agarose to each lysate, incubating on a rotator for 1 h at 41C, and centrifuging at 13 000 g for 5 min at 41C. After four washings with immunoprecipitation buffer, immunoprecipitates were solubilized in 40 ml boiling SDS sample buffer. Immunoprecipitates were also prepared from subconfluent cell cultures grown for the time specified in either the absence or presence of 100 nm PMA, as described previously .
Antisense ODN treatments
Phosphorothioate ODNs were obtained from Invitrogen. Sequences for the antisense PKCe and Bax ODNs, and corresponding scrambled control ODNs, were exactly as specified (Dibbert et al., 1999; Wu et al., 2002) . Subconfluent (70-80%) LNCaP and CWR-R1 cultures were washed with Opti-MEM 1 (Invitrogen) before introducing a mixture of ODN and Lipofectin (2 mg/ml; Invitrogen). Antisense and scrambled PKCe ODNs were used at a final concentration of 1 mm with the CWR-R1 cell line. A mixture of two antisense Bax ODNs were used at a final concentration of 5 mm and the pair of control scrambled Bax ODNs were used at an equimolar concentration. After 6 h at 371C, the cells were washed twice with serum-free medium and incubated for 56 h in Lipofectin-free media containing fresh ODN.
Apoptosis detection
Subconfluent LNCaP and LNCaP/e cells (3.5 Â 10 4 cells/well in 24-well plates) were cultured in complete medium for at least 24 h at 371C. Adherent cells were then incubated for an additional 20 h in fresh media, with or without PMA (100 nm). Apoptosis assays performed using the CWR-R1 cell line and an antisense PKCe ODN are described above. Apoptotic cells were identified using acridine orange and ethidium bromide staining, as before . In all, 100 cells were scored in triplicate for each cell line and treatment condition. Three independent experiments were conducted and data were expressed as the percentage of apoptotic cells.
Immunoblot analyses
Immunoblot analyses were performed as described previously (Prekeris et al., 1996) . Antibodies purchased from Santa Cruz Biotechnology were raised against Bax (N-20), cytochrome c (A-8) or PKCe (C-15). The conformation-sensitive monoclonal antibody raised against Bax (uBax 6A7) was purchased from Trevigen (Gaithersburg, MD, USA). Monoclonal antibodies specific for actin and mitochondrial porin were purchased from Oncogene (clone JLA20; San Diego, CA, USA) and Molecular Probes (clone 20B12; Eugene, OR, USA), respectively. The Western blot shown in Figure 3a was digitally analysed using BioRad Quantity One software (version 4; Hercules, CA, USA).
Immunohistochemical analysis of Bax and cytochrome c LNCaP (2 Â 10 4 ) and LNCaP/e (5 Â 10 3 ) cells were plated on 25-mm German glass coverslips (Electron Microscopy Sciences, Ft. Washington, PA, USA) in 10-cm dishes. Cells were incubated 48 h in RPMI, containing 10% FBS, before introducing either PMA (100 nm) or an equal volume of 0.1% dimethylsulfoxide (vehicle control). Following a 12 h exposure, the media was removed and coverslips were washed with 1 ml PBS, fixed with 3.7% paraformaldehyde (15 min), incubated with 0.2% Triton X-100 (5 min), blocked in 1% bovine serum albumin (5 min), and incubated with either 2.5 mg/ml anti-cytochrome c (556432; BD PharMingen) or 1.6 mg/ml anti-Bax (P-19; Santa Cruz Biotechnology) antibodies for 1 h; all steps were performed at room temperature. After a PBS wash, the slides were incubated in the dark with either 2 mg/ml goat anti-rabbit IgG TXRD conjugate (Southern Biotechnology Associates, Birmingham, AL, USA) or 3 mg/ml goat anti-mouse alexa conjugate (Molecular Probes, Eugene, OR, USA) for 45 min at room temperature. After another PBS wash, slides immunostained for Bax were incubated 15 min in PBS containing 100 nm Mitotracker Green FM (Molecular Probes). All coverslips were rinsed a final time with PBS and affixed to glass microscope slides using Prolong antifade fixative (Molecular Probes). Cells were examinedfor immunofluorescence using a LSM 510 confocal micro-scope (Zeiss, Jena, Germany) and LSM 5 Image Examiner software. Control slides were incubated with equimolar concentrations of goat anti-rabbit IgG TXRD or goat anti-mouse alexa conjugates alone and showed no immunoreactivity.
Subcellular fractionation and immunoblot analysis of cytochrome c distribution
Subconfluent LNCaP and LNCaP/e cells were cultured in complete medium for at least 24 h at 371C. Adherent cells were then incubated for an additional 20 h in fresh media, with or without PMA (100 nm). Adherent and floating cells were pooled and sedimented prior to their lysis in a buffer containing 20 mm HEPES (pH 7.5), 1.5 mm MgCl 2 , 1mm KCl, 1 mm EDTA, 1 mm EGTA, 1 mm DTT, and proteolytic inhibitors (Prekeris et al., 1996) and using 10 passes through a 26 gauge needle. Nuclei and cell debris were removed by sedimentation (1000 g for 5 min) before sedimenting the mitochondriaenriched heavy membrane (M) fraction by centrifugation (10 000 g for 10 min). Cytosolic (S) fractions were isolated from the resulting supernatant by centrifuging for 1 h at 100 000 g.
Immunohistochemical analysis of PKCe
Prostate specimens were acquired in compliance with the guidelines of the University of North Carolina at Chapel Hill Clinical Cancer Protocol Review Committee and Institutional Review Board (Chapel Hill, NC, USA). Histological diagnoses were verified by examination of frozen and corresponding formalin-fixed, paraffin-embedded tissues (Gregory et al., 1999) . Samples of BPH from 10 men were obtained from the transition zone of radical prostatectomy specimens. Samples of presumed androgen-dependent CaP were obtained from palpable tumor nodules in the radical prostatectomy specimens of 12 men with clinically localized disease. Samples of recurrent CaP were obtained by transurethral resection from 25 men who exhibited increasing serum prostate-specific antigen values and developed urinary retention from locally recurrent CaP more than 1 year after surgical castration. Formalin-fixed, paraffinembedded recurrent CaP samples were used to construct tissue microarrays. Sections of BPH and tissue arrays of CaP were processed for immunostaining by incubating the slides in a pressure cooker at 1001C (Biocare Medical, Walnut Creek, CA, USA) for 1 min 45 s, followed by preincubation in normal goat serum for 15 min at room temperature and a phosphatebuffered saline (PBS) wash. Slides were incubated with antihuman PKCe IgG at a 1 : 500 dilution for 1 h followed by incubation with goat anti-rabbit secondary antibody for 15 min. Immunoperoxidase reaction products were detected using diaminobenzidine. Specificity of immunostaining was determined by omitting the primary antibody or peptide competition of the primary antibody using PKCe (C-15P) blocking peptide (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Measurement of optical density
The imaging hardware consisted of a Zeiss Axioshop microscope (Carl Zeiss, Inc., Thornwood, NY, USA), a three-chip charge-coupled device camera (C5810; Hamamatsu Photonics, Inc.), and a Pentium-based personal computer. Histological images were acquired from immunopositive areas and images were analysed using Optimas 6.1 (Optimas Corp., Bothell, WA, USA). The image was converted from a 24-bit color (red, green, and blue) image to a 24-bit uncompressed (hue, saturation, and intensity) image type. Regions of 3 Â 3 pixel size were selected from 20 to 25 regions of each image. Immunopositive regions were collected from 10 different patient samples from BPH and recurrent CaP. The mean optical density of each region was determined and the mean optical density was calculated per patient sample.
Data analysis
Values shown are representative of three or more experiments, unless otherwise specified, and treatment effects were evaluated using a two-sided Student's t-test. Errors are standard errors of the mean (s.e.) of averaged results and values of Po0.05 were considered to represent a significant difference between means.
